Orforglipron
Orforglipron is an oral small-molecule GLP-1 receptor agonist that, unlike peptide GLP-1 drugs, can be taken as a daily tablet without strict food and water restrictions. Published Phase 2 trials in obesity and type 2 diabetes showed reductions in body weight and HbA1c, and the Phase 3 program (ATTAIN in obesity and ACHIEVE in type 2 diabetes) reported positive results. On the basis of the ATTAIN obesity program, the US FDA approved orforglipron (Foundayo) in April 2026 for chronic weight management. It is not yet approved for type 2 diabetes and is not yet authorized by the EMA or Australia's TGA.
Mechanism
In plain terms, orforglipron is a pill that mimics the gut hormone GLP-1, which lowers blood sugar and reduces appetite. Technically, it is a non-peptide small molecule that agonizes the GLP-1 receptor; because it is not a peptide it is orally bioavailable and does not require the injection or the fasting administration constraints of oral peptide GLP-1 drugs. Receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces food intake.
Regulatory Status by Region
- United States (FDA)Approved. The FDA approved orforglipron (Foundayo) on April 1, 2026 for chronic weight management in adults with obesity, or overweight with weight-related conditions, based on the ATTAIN Phase 3 program. A type 2 diabetes indication (ACHIEVE program) is not yet approved.
- Australia (TGA)Not entered on the Australian Register of Therapeutic Goods (ARTG); not yet approved for supply.
- European Union (EMA)Not authorized; no marketing authorization at this time.
- WADANot listed on the WADA Prohibited List. As a GLP-1 receptor agonist it is not a banned substance.
Key Studies
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (Wharton et al.) (N Engl J Med 2023;389:877-888)
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a phase 2 trial (Frias et al.) (Lancet 2023)